Insulin resistance in polycystic ovary syndrome

Current Opinion in Obstetrics and Gynecology

Volumn 9, Issue 3, 1997, Pages 193-201

  Prelevic, Gordana M ^a,b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b MIDDLESEX HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATHEROGENESIS; ATHEROSCLEROSIS; FEMALE; GLUCOSE TRANSPORT; HUMAN; INSULIN BLOOD LEVEL; INSULIN METABOLISM; INSULIN RESISTANCE; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; REVIEW;

EID: 0030856498     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-199706000-00011     Document Type: Review

References (99)

1. Poretsky L, Kalin MF: The gonadotrophic function of insulin. Endocrinol Rev 1987, 8:132-141.
2. Reaven GM: Pathophysiology of insulin resistance in human disease. Physiol Rev 1995, 75:473-486. An excellent and in-depth review of insulin resistance.
3. Poretsky L: On the paradox of insulin-induced hyperandrogenism in insulin-resistant states. Endocr Rev 1991, 12:3-11.
4. Archard C, Thiers J: Hirsuties and its link with glycolytic insufficiency (diabetes of bearded women) [in French]. Bull Acad Natl Med 1921, 86:51-85.
5. Kahn CR, Flier JS, Bar RS, Archer JA, Gorden P, Martin MM, Roth J: The syndrome of insulin resistance and acanthosis nigricans. N Engl J Med 1976, 294:739-745.
6. Taylor SI, Dons RF, Hernandez E: Insulin resistance associated with androgen excess in women with autoantibodies to insulin receptor. Ann Intern Med 1982, 97:851-854.
7. Burghen GA, Givens JR, Kitabchi AE: Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 1980, 50:113-116.
8. Chang RJ, Nakamura RM, Judd HL, Kaplan SA: Insulin resistance in nonobese patients with polycystic ovary syndrome. J Clin Endocrinol Metab 1983, 57:356-359.
9. Conway GS, Jacobs HS, Holly JMP, Wass JAH: Effects of luteinizing hormone, insulin, insulin-like growth factor-I and insulin-like growth factor small protein I in polycystic ovary syndrome. Clin Endocrinol 1990, 33:593-603.
10. Robinson S, Kiddy D, Gelding SV, Willis D, Niththyananthan R, Bush A, Johnston DG, Franks S: The relationship of insulin insensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries. Clin Endocrinol 1993, 39:351-355.
11. Dunaif A, Segal KR, Futterweit W, Dobrjansky A: Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989, 38:1165-1174.
12. Dunaif A, Graf M, Mandeli J, Laumas V, Dobrjansky A: Characterisation of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance and/or hyperinsulinemia. J Clin Endocrinol Metab 1987, 65:499-507.
13. Bringer J, Lefebvre P, Boulet F, Grigorescu F, Renard E, Hedon B, Orsetti A, Jaffiol C: Body composition and regional fat distribution in polycystic ovarian syndrome. Relationship to hormonal and metabolic profiles. Ann N Y Acad Sci 1993, 687:115-123.
14. Rebuffe-Scrive M, Bronnegard M, Nilsson A, Lindstaed G, Bjorntorp P: Anthropometric variables and metabolism in polycystic ovarian disease. Horm Metab Res 1989, 21:391-397.
15. Kiddy DS, Hamilton-Fairley D, Bush A, Short F, Amyaoku V, Reed MJ, Franks S: Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol 1992; 36: 105-111.
16. Holte J, Berg T, Berne C, Berglund L, Lithell H: Enhanced early insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome and normal glucose tolerance. J Clin Endocrinol Metab 1994, 78:1052-1058.
17. O'Meara N, Blackman JD, Ehrmann DA, Barnes RB, Jaspan JB, Rosenfield RL, Polinsky KS: Defects in beta cell function and insulin action in functional ovarian hyperandrogenism. J Clin Endocrinol Metab 1993, 76:1241-1247.
18. Ehrmann DA, Sturis J, Byrne MM, Karrison T, Rosenfield RL, Polonsky KS: Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent dibetes mellitus. J Clin Invest 1995, 96:520-527.
19. Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer JP: Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects: evidence for a hyperbolic function. Diabetes 1993, 42:1663-1672.
20. Prelevic GM, Wurzburger MI, Balint-Peric LA, Ginsburge J: Twenty-four-hour serum growth hormone, insulin, C-peptide and blood glucose profiles and serum insulin-like growth factor-I concentrations in women with polycystic ovaries. Horm Res 1992, 37:125-131.
21. Landon J, Wynn V, Houghton BJ, Cooke JNC: Effects of anabolic steroid, methandienone on carbohydrate metabolism in man. II Effect on methandienone on response to glucagon, adrenalin and insulin in the fasted subjects. Metabolism 1962, 11:513-523.
22. Marin P, Darin N, Amemiya T, Andersson B, Jern S, Bjorntorp P: Cortisol secretion in relation to body fat distribution in obese premenopasual women. Metabolism 1992, 41:882-886.
23. Bjorntorp P: Abdominal obesity and risk. Clin Exp Hypertens 1990, 12:783-794.
24. Laatikainen TJ, Titinen AE, Salmien LK, Pekonen F: Response of plasma beta-endorphin and insulin to oral glucose tolerance test in non-obese women with polycystic ovaries. Gynecol Endocrinol 1989, 3:241-247.
25. Lanzone A, Fulghesu AM, Cucinelli F, Ciampelli M, Caruso A, Mancuso S: Evidence of a distinct derangement of opioid tone in hyperinsulinemic patients with polycystic ovarian syndrome: relationship with insulin and luteinizing hormone secretion. J Clin Endocrinol Metab 1995, 80:3501-3506.
26. Fulgesu AM, Lanzone A, Cucinelli F, Caruso A, Mancuso S: Long term naltrexene treatment reduces the exaggerated insulin secretion in patients with polycystic ovary disease. Obstet Gynecol 1993, 82:191-197.
27. Lanzone Z, Fulgesu AM, Fortini A, Cutillo G, Cucinelli F, Di Simone N, Camso A, Mancuso S: Effect of opiate receptor blockade on the insulin response to oral glucose load in polycystic ovarian disease. Hum Reprod 1991, 6:1043-1049.
28. Giugliano D, Ceriello A, Salvatore T, Paolisso G, D'Onofrio F, Lefevre PJ: Beta endrophin infusion restores acute insulin response to glucose in type II diabetes mellitus. J Clin Endocrinol Metab 1978, 64:944-948.
29. Anttila L, Ding YQ, Ruutiainen K, Erkkola R, Irjala K, Huhtaniemi I: Clinical features and circulating gonadotropin, insulin and androgen interactions in women with polycystic ovarian disease. Fertil Steril 1991, 55:1057-1061.
30. Dale PO, Tanbo T, Vaaler S, Abyholm T: Body weight hyperinsulinaemia and gonadotropins in the polycystic ovarian syndrome: evidence of two distinct populations. Fertil Steril 1992, 58:487-491.
31. Conway GS, Jacobs HS: Clinical implications of hyperinsulinaemia in women. Clin Endocrinol 1993, 39:623-632.
32. Prelevic GM, Wurzburger MI, Balint-Peric LA: LH pulsatility and response to a single s.c. injection of buserelin in polycystic ovary syndrome. Gynecol Endocrinol 1990, 4:1-13.
33. Nestler JE, Jakubowitz DJ: Decreases in ovarian cytochrome P450c17alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996, 335:617-623. An important study that provides evidence on mechanisms of insulin effect on ovarian steroidogenesis.
34. Adashi EY, Hsueh AJW, Yen SSC: Insulin enhancement of luteinizing hormone and follicle stimulating hormone release by cultured pituitary cells. Endocrinology 1981, 108:1441-1449.
35. Cara JF, Rosenfield RL: Insulin-like growth factor I and insulin potentiate luteinizing-hormone-induced androgen synthesis by rat ovarian thecal-intestitial cells. Endocrinology 1988, 123:733-739.
36. Hernandez ER, Resnick CE, Svoboda ME, Van Wyk JJ, Payne DW, Adashi EY: Somatomedin C insulin-like growth factor I as an enhancer of androgen biosynthesis by cultured rat oavrian cells. Endocrinology 1988, 122:1603-1612.
37. Barbieri RL: Polycystic ovarian disease. Annu Rev Med 1991, 42:199-204.
38. Prelevic GM, Wurzburger MI, Balint-Peric LJ, Nesic J: Inhibitory effect of sandostatin on luteinising hormone and ovarian steroids in polycystic ovary syndrome. Lancet 1990, 336:900-903.
39. Nestler JE, Barlascini CO, Matt DW, Steingold KA, Plymate SR, Clore LN, Blackard WG: Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 1989, 68:1027-1032.
40. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ: Metformin therapy in polycystic ovary syndrome reduces hyperinsulinaemia, insulin resistance, hyperandrogenaemia and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994, 43:647-654.
41. Barbieri RL, Makris A, Randall RW, Daniels G, Kistner RW, Ryan KJ: Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab 1986, 62:904-910.
42. Adashi EY, Resnik CE, D'Ercole AJ, Svoboda ME, Van Wykk JJ: Insulin-like growth factors as intraovarian regulators of granulosa cell growth and induction. Endocr Rev 1985, 6:400-420.
43. Daughday WH, Phillips LS, Mueller MC: The effects of insulin and growth hormone on the release of somatomedin by isolated rat liver. Endocrinology 1976, 98:1214-1219.
44. Suikkari AM, Koivisto VA, Rutanen EM, Yki-Jarvinen H, Karonen SL, Seppala M: Insulin regulates the serum levels of low molecular weight insulin-like growth factor-binding protein. J Clin Endocrinol Metab 1988, 66:266-272.
45. Suikkari AM, Ruutiainen K, Erkkola R, Seppala M: Low levels of low molecular weight insulin-like growth factor binding protein in patients with polycystic ovarian disease. Hum Reprod 1989, 4:136-139.
46. Iwashita M, Mimuro T, Watanabe M, Setoyama T, Matsuo A, Adachi T, Takeda Y, Sakamoto S: Plasma levels of insulin-like growth factor I and its binding protein in polycystic ovary syndrome. Horm Res 1990, 33(suppl 2):21-26.
47. Holly JMP, Eden JA, Alagband-Zadeh J, Carter GD, Jemmott RC, Cianfarani S, Chard T, Wass JD: Insulin-like growth factor binding proteins in follicular fluid from normal dominant and cohort follicles, polycystic and multicystic ovaries. Clin Endocrinol 1990, 33:53 -54.
48. Jalkanen J, Suikkari AM, Koistinen R, Butzow R, Ritvos O, Seppala M, Ranta T: Regulation of insulin-like growth factor-binding protein-1 production in human granulosa-luteal cells. J Clin Endocrinol Metab 1989, 69:1174-1179.
49. Conover CA, Lee PDK: Insulin regulation of insulin-like growth factor-binding protein production in cultured HepG2cells. J Clin Endocrinol Metab 1990, 70:1062-1067.
50. Willis D, Franks SD: Insulin action in human granulosa cells from normal and polycystic ovaries is mediated by the insulin receptor and not the type-I insulin-like growth factor receptor. J Clin Endocrinol Metab 1995, 80:3788-3790. An outstanding paper on the mechanisms of insulin action in the granulosa cells.
51. Pasquali R, Venturoli S, Paradisi R, Capelli M, Parenti N, Melchionda N: Insulin and C-peptide levels in obese patients with polycystic ovaries. Horm Metab Res 1983, 14:282-287.
52. Prelevic GM, Wurzburger MI, Peric LJA: Pancreatic beta cell function in polycystic ovary syndrome: its relationship to body weight, serum testosterone and serum prolactin levels. Exp Clin Endocrinol 1987, 90:76-82.
53. Dunaif A, Mandeli J, Fluhr H, Dobrjansky A: The impact of obesity and chronic hyperinsulinaemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome. J Clin Endocrinol Metab 1988, 66:131-139.
54. Micic D, Popovic V, Nesovic M, Sumarac M, Dragasevic M, Kendereski A, Markovic D, Djordjevic P, Manojlovic D, Micic J: Androgen levels during sequential insulin euglycemic clamp studies in patients with polycystic ovarian disease. J Steroid Biochem 1988, 31:995-999.
55. Dunaif A, Green G, Futterweitt W, Dobrjansky A: Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in the polycystic ovary syndrome. J Clin Endcorinol Metab 1990, 70:699-704.
56. Nagamani M, Dinh TV, Kelver ME: Hyperinsulinaemia in hyperthecosis of the ovaries. Am J Obstet Gynecol 1986, 154:384-387.
57. Geffner ME, Kaplan SA, Bersch N, Golde DW, Landon EM, Chang RJ: Persistance of insulin resistance in polycystic ovarian disease after inhibition of ovarian steroid secretion. Fertil Steril 1986, 45:327-333.
58. Nestler JE, Clore JN, Strauss JF III, Blackard WG: Effects of hyperinsulinaemia on serum testosterone, progesterone, dehydroepiandrosterone sulphate and cortisol levels in normal women and in a woman with hyperandrogenism, insulin resistance and acanthosis nigricans. J Clin Endcorinol Metab 1987, 64:180-184.
59. Falcone T, Finegood DT, Fantus IG, Morris D: Androgen response to endogenous insulin secretion during the frequently sampled intravenous glucose tolerance test in normal and hypernandrogenic women. J Clin Endcorinol Metab 1990, 71:1653-1657.
60. Buffington CK, Kitabchi AE: Evidence for a defect in insulin metabolism in hyperandrogenic women with polycystic ovarian syndrome. Metabolism 1994, 43:1367-1372.
61. Polderman KH, Gooren UG, Asscheman H, Bakker A, Heine RJ: Induction of insulin resistance by androgens and estrogens. J Clin Endocnnol Metab 1994, 79:265-271.
62. Shoupe D, Kumar DD, Lobo RA: Insulin resistance in polycystic ovary syndrome. Am J Obstet Gynecol 1983, 147:588-592.
63. Nestler JE, Strauss JF: Insulin as an effector of human ovarian and adrenal steroid metabolism. Endocrinol Metab Clin N Am 1991, 20:807-823.
64. Carey AH, Chan KL, Short F, White D, Williamson R, Franks S: Evidence for a single gene effect causing polycystic ovaries and male pattern baldness. Clin Endocrinol 1993, 38:653-658.
65. Utiger RD: Insulin and the polycystic ovary syndrome. N Engl J Med 1996, 335:657-658. An excellent summary on current understanding of insulin involvement in ovarian steroidogenesis.
66. Kahn CR, White MF: The insulin receptor and the molecular mechanism of insulin action. J Clin Invest 1988, 82:1151-1156.
67. Moller DE, Flier JS: Insulin resistance: mechanisms, syndromes and implications. N Engl J Med 1991, 325:938-948.
68. Taylor SI, Cama A, Accili D, Barbetti F, Ouon MJ, de la Sierra M, Suzuki I, Koller E, Levy-Toledano R, Wertheimer E: Mutations in the insulin receptor gene. Endocr Rev 1992, 13:566-595.
69. Sobrara LR, Tang Z, Cama A, Xia J, Schenker E, Kohanski RA, Poretsky L, Koller E, Taylor S, Dunaif A: Absence of insulin receptor gene mutations in three insulin-resistant women with the polycystic ovary syndrome. Metabolism 1994, 43:1568-1574.
70. Conway GS, Avey C, Rumsby G: The tyrosine kinase domain of the insulin receptor gene is normal in women with hyperinsulinaemia and polycystic ovary syndrome. Hum Reprod 1994, 9:1681-1683.
71. Talbot JA, Bicknell EJ, Rajkhowa M, Krook A, O'Rahilly S, Clayton RN: Molecular scanning of the insulin receptor gene in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1996, 81:1979-1983.
72. Dunaif A, Segal KR, Shelly DR, Green G, Dobrjansky A, Licholai T: Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 1992, 41:1257-1266.
73. Rosenbaum D, Haber RS, Dunaif A: Insulin resistance in polycystic ovary syndrome: decreased expression of GLUT4 glucose transporters in adipocytes. Am J Physiol 1993, 264:E197-E202.
74. Ciaraldi TP, El-Roeiy A, Madar Z, Reichart D, Olefsky JM, Yen SS: Cellular mechanisms of insulin resistance in polycystic ovary syndrome. J Clin Endocrinol Metab 1992, 75:577-583.
75. Dunaif A: Insulin resistance and ovarian hyperandrogenism. Endocrinologist 1992, 2:248-260.
76. Dunaif A: Hyperandrogenic anovulation (PCOS): a unique disorder of insulin action associated with an increased risk of non-insulin-dependent diabetes mellitus. Am J Med 1995, 98(suppl 1A):33S-39S. An excellent review of molecular mechanisms of insulin resistance in PCOS.
77. Dunaif A, Xia J, Book CB, Schenker E, Tang Z: Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 1995, 96:801-810. A potential new mechanism for insulin resistance in PCOS.
78. Moghetti P, Castello R, Negri C, Tosi F, Spiazzi GG, Brun E, Balducci R, Toscano V, Muggeo M: Insulin infusion amplifies 17alpha-hydroxycorticosteroid intermediates response to adrenocorticotropin in hyperandrogenic women: apparent relative impairment of 17,20-lyase activity. J Clin Endocrinol Metab 1996, 81:881-886. An important study that provides a possible explanation for insulin-induced hyperandrogenaemia.
79. Zhang LH, Rodriguez H, Ohno S, Miller WL: Serine phosphorylation of human P450C17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome. Proc Natl Acad Sci 1995, 92:10619-10623.
80. Pyörälä K: Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 1979, 2:131-141.
81. Zavaroni L, Dallaglio E, Bonara E, Alpi O, Passen M, Reaven GM: Evidence that multiple risk factors for coronary artery disease exist in persons with abnormal glucose tolerance. Am J Med 1987, 83:609-612.
82. Stout RW: Insulin as a mitogenic factor: role in the pathogenesis of cardiovascular disease. Am J Med 1991, 90:62S-65S.
83. Wild RA: Obesity, lipid, cardiovascular risk and androgen excess. Am J Med 1995, 98(suppl 1A):27S-32S.
84. Wild RA, Painter PD, Coulson PB, Carruth KB, Ranney GB: Lipoprotein lipid concentrations as cardiovascular risk in patients with polycystic ovary syndrome. J Clin Endocrinol Metab 1985, 61:946-950.
85. Conway GS, Agrawall R, Betteridge DJ, Jacobs HS: Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol 1992, 37:119-126.
86. Talbott E, Guzick D, Clerici A, Berga S, Detre K, Weimer K, Kuller L: Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb 1995, 15:821-826.
87. von Eckardstein S, von Eckardstein A, Bender HG, Schulte H, Assman G: Elevated low-density lipoprotein-cholesterol in women with polycystic ovary syndrome. Gynecol Endocrinol 1996, 10:311-318.
88. Meirow D, Raz I, Yossepowitch O, Brzezinski A, Rosler A, Schenker JG, Berry EM: Dyslipidaemia in polycystic ovarian syndrome: different groups, different aetiologies. Hum Reprod 1996, 11:1848-1853.
89. Rajkhowa M, Bicknell J, Jones M, Clayton RN: Insulin sensitivity in women with polycystic ovary syndrome: relationship to hyperandrogenemia. Fertil Steril 1994, 61:605-612.
90. Dahlgren E, Johansson S, Lindstedt G, Knutsson F, Oden A, Janson PO, Mattson LA, Crona N, Lundberg PO: Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long term follow up focusing on natural history and circulating hormones. Fertil Steril 1992, 57:505-513.
91. Prelevic GM, Wood J, Okolo S, Ginsburg S: Peripheral blood flow in young women with the polycystic ovary syndrome [Abstract]. J Endocrinol 1996, 151(suppl):13.
92. Holte J, Gennarelli G, Berne C, Bergh C, Lithell H: Elevated ambulatory blood pressure in women with polycystic ovary syndrome: a sign of a prehypertensive state. Hum Reprod 1996, 11:23-28.
93. Sampson M, Kong C, Patel A, Unwin R, Jacobs HS: Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clin Endocrinol 1996, 45:623-629.
94. Dahlgren E, Janson PO, Johansson S, Lapidus L, Oden A: Polycystic ovary syndrome and risk for myocardial infarction: evaluated from a risk factor model based on a prospective study of women. Acta Obstet Gynecol Scand 1992, 71:599-604.
95. Wild RA, Grubb B, Hartz A, Van Nort JJ, Bachman W, Bartholomew M: Clinical signs of androgen excess as risk factors for coronary artery disease. Fertil Steril 1990, 54:255-259.
96. Prelevic GM, Beljic T, Balint-Peric LJ, Ginsburg J: Cardiac flow velocity in women with the polycystic ovary syndrome. Clin Endocrinol 1995, 43:677-681.
97. Prelevic GM, Beljic T: The effect of oestrogen and progestogen replacement therapy on systolic flow velocity in healthy postmenopausal women. Maturitas 1994, 20:167-174.
98. Jacobs HS: Polycystic ovary syndrome: the present position. Gynecol Endocrinol 1996, 10:427-433. An excellent review of PCOS with particular reference to clinical implications of hyperinsulinaemia.
99. Dahlgren E, Janson PO, Johansson T, Lapidus L, Linstedt G, Tengborn L: Haemostatic and metabolic variables in women with polycystic ovary syndrome. Fertil Steril 1994, 61:455-460.